FIELD: medicine, dermatology. SUBSTANCE: invention proposes oral administration of bromocriptine at the dose 5.0-7.5 mg per 24 h and α-thyroxine at the dose 25-75 mg per 24 h for total treatment course. Also, in addition to basic preparation antistrumin is prescribed at the dose 2000 mg per a week orally for 3-6 months and vitamin E by intramuscular route at the dose 1.0 ml for 20 days. EFFECT: enhanced effectiveness of treatment, stable remission, decreased probability of adverse responses. 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF TREATMENT OF PSORIASIS | 2005 |
|
RU2302193C1 |
| METHOD OF TREATING ACNE | 2012 |
|
RU2495675C1 |
| METHOD TO TREAT PATIENTS SUFFERING AUTOIMMUNE THYROIDITIS | 2000 |
|
RU2180587C1 |
| METHOD FOR SELECTING THERAPEUTIC APPROACH TO ACNE IN FEMALES | 2012 |
|
RU2529789C2 |
| METHOD FOR ESTIMATING PREOPERATIVE THYROTOXICOSIS PATIENTS READINESS DEGREE | 2000 |
|
RU2191386C2 |
| METHOD FOR INTEGRATED TREATMENT OF OBESITY ACCOMPANYING POLYCYSTIC OVARY SYNDROME | 2014 |
|
RU2564439C1 |
| DIFFUSE TREATMENT METHOD | 2000 |
|
RU2172635C1 |
| METHOD OF DERMATOSIS DEVELOPMENT PREDICTION IN WOMEN WITH SCLEROPOLYCYSTIC OVARIAN SYNDROME (SPCO) | 2008 |
|
RU2367954C1 |
| METHOD FOR TREATING AUTOIMMUNE THYROIDITIS WITH CYCLOFERON | 2006 |
|
RU2306932C1 |
| DIAGNOSTIC TECHNIQUE FOR HYPERANDROGENISM SYNDROME IN WOMEN OF REPRODUCTIVE AGE | 2010 |
|
RU2461354C2 |
